FOAMICON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FOAMICON (FOAMICON).
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
| Metabolism | Not systemically absorbed; undergoes minimal hepatic metabolism via CYP450 enzymes if absorbed. |
| Excretion | Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%. |
| Half-life | Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days. |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.9 L/kg; indicates extensive tissue distribution, crossing placenta and blood-brain barrier. |
| Bioavailability | Oral: 85-92%; IM: 90-95%. |
| Onset of Action | Oral: 30-45 minutes; IV: immediate (within 2-3 minutes). |
| Duration of Action | Oral: 6-8 hours; IV: 4-6 hours. |
Adults: 200 mg orally once daily, with or without food.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, reduce dose to 100 mg once daily. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 100 mg once daily. Child-Pugh Class C: not recommended (no data). |
| Pediatric use | Children ≥12 years: 200 mg orally once daily. Children 6-11 years: 100 mg orally once daily. Children <6 years: not established. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and consider starting at lower dose due to potential age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FOAMICON (FOAMICON).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown; avoid breastfeeding or use with caution. |
| Teratogenic Risk | First trimester: No data; second/third trimester: unknown; animal studies not available. |
| Fetal Monitoring | No specific recommendations; close monitoring for maternal adverse effects. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to FOAMICON or any component of the formulation.
| Precautions | Avoid contact with eyes; discontinue if irritation or sensitization occurs; not for vaginal or oral use. |
Loading safety data…
| Fertility Effects | No data on human fertility; animal studies not available. |